1 / 18

Defining Cancer Recurrence in a Population-Based Cancer Surveillance Study

Defining Cancer Recurrence in a Population-Based Cancer Surveillance Study. Trevor D. Thompson . Mathematical Statistician Cancer Surveillance Branch. NAACCR Conference 2019. June 13, 2019 Vancouver, British Columbia, Canada. Background.

amil
Download Presentation

Defining Cancer Recurrence in a Population-Based Cancer Surveillance Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Defining Cancer Recurrence in a Population-Based Cancer Surveillance Study Trevor D. Thompson Mathematical Statistician Cancer Surveillance Branch NAACCR Conference 2019 June 13, 2019 Vancouver, British Columbia, Canada

  2. Background • Cancer recurrence is an important outcome not routinely captured by population-based registries • Difficult time to event outcome to define • Who is eligible for a recurrence? • When to start the time to event clock (i.e. when are patients at risk)? • When to censor? • Assume disease-free through active follow-up date (last review of medical records) unless otherwise documented? • At last documented disease-free date – clinical follow-up schedules vary • Should cause of death information figure in?

  3. NPCR Patient-Centered Outcomes Research (PCOR) • Five US states (CO, LA, ID, NH, RI) • Outcomes of interest – disease-free (DF) status, recurrence, and progression • Active follow-up of medical records for a minimum of 32 months post-diagnosis with the majority followed at least 60 months • N=17,802 breast and colorectal cancer cases diagnosed in 2011

  4. NPCR Patient-Centered Outcomes Research (PCOR) • Recurrence Status • Coding: • 0 = Patient never found to be DF • 1 = Found to be DF and remained DF till the end of study • 2 = Documented Recurrence • 3 = Uncertain if recurrence based on incomplete documentation • 4 = Uncertain if recurrence based on conflicting documentation • 9 = Unknown; patient was DF but unclear if remained DF or recurred • First recurrence date • Type of recurrence (in situ, local, regional, distant) • Recurrence source

  5. Study Population • Include only: • First primary diagnosed in study period • Surgery patients • Achieved DF status (at risk for recurrence) • Known stage • Exclude patients with no follow-up time: • Missing surgery or recurrence date • Unknown recurrence status and last DF date = surgery date • N=9826 female breast cancers and N=3770 colorectal cancers

  6. Methods • Outcomes: • Time from surgery to recurrence • Time from surgery to death or recurrence • Censoring Methods/Assumptions: • Assume no recurrence through active follow-up (AFU) date • Censor at last documented DF date • Used SEER Cause-Specific Death Classification as part of outcome algorithm • Uses ICD codes to define cancer deaths for first primaries • 0=Alive or dead of other cause, 1=Dead attributable to cancer DX • We used cancer-specific COD only for sequence numbers 02+

  7. Methods • Discrete variables presented as frequencies and percentages; continuous variables presented as 25th / 50th / 75th percentiles • Freedom from recurrence and recurrence-free survival presented as Kaplan-Meier estimates/figures • Estimates censored at 4-years where follow-up was relatively complete

  8. Events Algorithm – AFU Assumption • Patients with a documented recurrence classified as both events at date of recurrence • Patients classified as DF until end of study according to abstractor • Patients that were DF but unclear if remained DF until end of study • R = Recurrence, DR = Death or Recurrence * According to SEER Cause-Specific Death algorithm

  9. Events Algorithm – Documented DF • Patients with a documented recurrence classified as both events at date of recurrence • Patients classified as DF until end of study according to abstractor • Patients that were DF but unclear if remained DF until end of study • R = Recurrence, DR = Death or Recurrence * According to SEER Cause-Specific Death algorithm

  10. Study Population - Demographics

  11. Study Population – AJCC Stage

  12. 4-year Freedom from Breast Cancer Recurrence by AJCC Stage

  13. 4-year Freedom from Colorectal Cancer Recurrence by AJCC Stage

  14. Summary: 4-Year Recurrence-Free Survival

  15. Summary • PCOR dataset provides a unique opportunity to analyze cancer recurrence in a population-based setting • Active follow-up of medical records with directly coded disease-free, recurrence, and progression status • Recurrence is a difficult outcome to define • Important to weigh the pros/cons of definitions/algorithms and acknowledge limitations • Recurrence-free survival presents additional challenge of shorter follow-up for recurrence compared to death (via linkages)

  16. Summary • Recommend using active follow-up date in definitions rather than last DF date • Logically makes sense given the nature of the PCOR data collection (abstractors reviewing records and directly coding recurrence status) • Results in less censoring - increases % with complete follow-up • Yielded similar results for recurrence and recurrence-free survival compared to documented DF dates • Recommend using cause of death information as part of algorithms

  17. Funding: This work was supported by the Patient Centered Outcome Research Trust Fund through CDC Cooperative Agreements of the National Program of Cancer Registries: in conjunction with the participating states and a CDC Patient Centered Outcome Research contract to ICF Acknowledgements

More Related